PlainRecalls
FDA Drug Moderate Class II Ongoing

chlorproMAZINE Hydrochloride Tablets, USP 100 mg, Rx Only, 100 Tablets per bottle, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-864-01

Reported: April 9, 2025 Initiated: March 11, 2025 #D-0309-2025

Product Description

chlorproMAZINE Hydrochloride Tablets, USP 100 mg, Rx Only, 100 Tablets per bottle, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-864-01

Reason for Recall

CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.

Details

Units Affected
8160 bottles
Distribution
Nationwide in the USA and PR
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
chlorproMAZINE Hydrochloride Tablets, USP 100 mg, Rx Only, 100 Tablets per bottle, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-864-01. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 8160 bottles.
Why was this product recalled?
CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 9, 2025. Severity: Moderate. Recall number: D-0309-2025.